Perceived morbidity and community burden after a Chikungunya outbreak: the TELECHIK survey, a population-based cohort study
- PMID: 21235760
- PMCID: PMC3029216
- DOI: 10.1186/1741-7015-9-5
Perceived morbidity and community burden after a Chikungunya outbreak: the TELECHIK survey, a population-based cohort study
Abstract
Background: Persistent disabilities are key manifestations of Chikungunya virus (CHIKV) infection, especially incapacitating polyarthralgia and fatigue. So far, little is known about their impact on health status. The present study aimed at describing the burden of CHIKV prolonged or late-onset symptoms on the self-perceived health of La Réunion islanders.
Methods: At 18 months after an outbreak of Chikungunya virus, we implemented the TELECHIK survey; a retrospective cohort study conducted on a random sample of the representative SEROCHIK population-based survey. A total of 1,094 subjects sampled for CHIKV-specific IgG antibodies in the setting of La Réunion island in the Indian Ocean, between August 2006 and October 2006, were interviewed about current symptoms divided into musculoskeletal/rheumatic, fatigue, cerebral, sensorineural, digestive and dermatological categories.
Results: At the time of interview, 43% of seropositive (CHIK+) subjects reported musculoskeletal pain (vs 17% of seronegative (CHIK-) subjects, P < 0.001), 54% fatigue (vs 46%, P = 0.04), 75% cerebral disorders (vs 57%, P < 0.001), 49% sensorineural impairments (vs 37%, P = 0.001), 18% digestive complaints (vs 15%, P = 0.21), and 36% skin involvement (vs 34%, P = 0.20) on average 2 years after infection (range: 15-34 months). After controlling for confounders such as age, gender, body mass index or major comorbidities in different Poisson regression models, 33% of joint pains were attributable to CHIKV, 10% of cerebral disorders and 7.5% of sensorineural impairments, while Chikungunya did not enhance fatigue states, digestive and skin disorders.
Conclusions: On average, 2 years after infection 43% to 75% of infected people reported prolonged or late-onset symptoms highly attributable to CHIKV. These manifestations carry a significant burden in the community in the fields of rheumatology, neurology and sensorineural health.
Figures
Similar articles
-
[Perceived morbidity and community burden of chikungunya in La Reunion].Med Trop (Mars). 2012 Mar;72 Spec No:76-82. Med Trop (Mars). 2012. PMID: 22693934 French.
-
Rheumatism and chronic fatigue, the two facets of post-chikungunya disease: the TELECHIK cohort study on Reunion island.Epidemiol Infect. 2018 Apr;146(5):633-641. doi: 10.1017/S0950268818000031. Epub 2018 Feb 28. Epidemiol Infect. 2018. PMID: 29486812 Free PMC article.
-
Impact of Chikungunya virus infection on health status and quality of life: a retrospective cohort study.PLoS One. 2009 Nov 11;4(11):e7800. doi: 10.1371/journal.pone.0007800. PLoS One. 2009. PMID: 19911058 Free PMC article.
-
Chikungunya fever: a re-emerging viral infection.Indian J Med Microbiol. 2008 Jan-Mar;26(1):5-12. doi: 10.4103/0255-0857.38850. Indian J Med Microbiol. 2008. PMID: 18227590 Review.
-
[Chikungunya on Reunion Island: chronicle of an epidemic foretold].Presse Med. 2006 Apr;35(4 Pt 2):641-6. doi: 10.1016/s0755-4982(06)74657-7. Presse Med. 2006. PMID: 16614609 Review. French.
Cited by
-
Alphaviruses: population genetics and determinants of emergence.Antiviral Res. 2012 Jun;94(3):242-57. doi: 10.1016/j.antiviral.2012.04.002. Epub 2012 Apr 19. Antiviral Res. 2012. PMID: 22522323 Free PMC article. Review.
-
First Chikungunya Outbreak in Suriname; Clinical and Epidemiological Features.PLoS Negl Trop Dis. 2016 Apr 15;10(4):e0004625. doi: 10.1371/journal.pntd.0004625. eCollection 2016 Apr. PLoS Negl Trop Dis. 2016. PMID: 27082985 Free PMC article.
-
Development and Validation of a Quantitative, One-Step, Multiplex, Real-Time Reverse Transcriptase PCR Assay for Detection of Dengue and Chikungunya Viruses.J Clin Microbiol. 2016 Jul;54(7):1766-1773. doi: 10.1128/JCM.00299-16. Epub 2016 Apr 20. J Clin Microbiol. 2016. PMID: 27098955 Free PMC article.
-
Chikungunya Virus and Its Envelope Protein E2 Induce Hyperalgesia in Mice: Inhibition by Anti-E2 Monoclonal Antibodies and by Targeting TRPV1.Cells. 2023 Feb 9;12(4):556. doi: 10.3390/cells12040556. Cells. 2023. PMID: 36831223 Free PMC article.
-
Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.J Clin Invest. 2017 Mar 1;127(3):737-749. doi: 10.1172/JCI84417. Epub 2017 Mar 1. J Clin Invest. 2017. PMID: 28248203 Free PMC article. Review.
References
-
- Porterfield JH. In: Antigenic characteristics and classification of the Togaviridae. Schlesinger R, editor. New York, NY: Academic Press; 1980. pp. 13–46.
-
- Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana-Seisdedos F, Desprès P, Michault A, Albert ML, Schwartz O. Characterization of remerging Chikungunyavirus. PLoS Pathog. 2007;3:e89. doi: 10.1371/journal.ppat.0030089. - DOI - PMC - PubMed
-
- Ozden S, Huerre M, Riviere JP, Coffey LL, Afonso PV, Mouly V, de Monredon J, Roger JC, El Amrani M, Yvin JL, Jaffar MC, Frenkiel MP, Sourisseau M, Schwartz O, Butler-Browne G, Desprès P, Gessain A, Ceccaldi PE. Human muscle satellite cells as targets of Chikungunya virus infection. PLoS One. 2007;2:e527. doi: 10.1371/journal.pone.0000527. - DOI - PMC - PubMed
-
- Manimunda SP, Vijayachari P, Uppoor R, Sugunan AP, Singh SS, Rai SK, Sudeep AB, Muruganandam N, Chaitanya IK, Guruprasad DR. Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans R Soc Trop Med Hyg. 2010;104:392–399. doi: 10.1016/j.trstmh.2010.01.011. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
